LSBCF (LakeShore Biopharma Co) Net Income (Continuing Operations): $-13.72 Mil (TTM As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is LakeShore Biopharma Co Net Income (Continuing Operations)?

LakeShore Biopharma Co LSBCF Net Income (Continuing Operations) is $-13.72 Mil as of Mar. 2025.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. LakeShore Biopharma Co's Net Income (Continuing Operations) for the six months ended in Mar. 2025 was $-16.63 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 was $-13.72 Mil.

LakeShore Biopharma Co  (OTCPK:LSBCF) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

LakeShore Biopharma Co Net Income (Continuing Operations) Related Terms

LakeShore Biopharma Co Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Net Income (Continuing Operations) Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Net Income (Continuing Operations)
-29.46 -16.71 -21.11 -60.19 -13.79

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only -19.50 -23.91 -35.96 2.91 -16.63

LakeShore Biopharma Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-13.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-13.72 Mil mean?
LakeShore Biopharma Co (LSBCF) has a Net Income (Continuing Operations) of $-13.72 Mil as of Mar. 2025. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on LakeShore Biopharma Co and its competitors.
Is LakeShore Biopharma Co's Net Income (Continuing Operations) too high?
LakeShore Biopharma Co's current Net Income (Continuing Operations) is $-13.72 Mil.
How does LakeShore Biopharma Co's Net Income (Continuing Operations) compare to ACUT and PPCB?
LakeShore Biopharma Co's Net Income (Continuing Operations) of $-13.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Net Income (Continuing Operations) is $-13.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Net Income (Continuing Operations) of $-13.72 Mil. The current Net Income (Continuing Operations) is $-13.72 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Net Income (Continuing Operations) is $-13.72 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.